{"filing":{"accession_number":"0001213900-26-096480","cik":"0001536196","ticker":"CANF","company_name":"Can-Fite BioPharma Ltd.","form":"6-K","filing_date":"2026-09-02","report_date":"2026-09-02","primary_document":"ea0304383-6k_canfite.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1536196/000121390026096480/ea0304383-6k_canfite.htm"},"events":[{"id":31196,"run_id":28616,"accession_number":"0001213900-26-096480","anchor_item_number":"EX-99.1","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Can-Fite announced entry into a definitive agreement for immediate exercise of warrants to purchase 1,591,738 ADSs at a reduced exercise price of $2.50 per ADS, generating approximately $4.0 million in gross proceeds. In consideration, the company will issue new unregistered warrants to purchase 3,183,476 ADSs—a 2:1 warrant issuance that is dilutive to existing shareholders. The new warrants are offered in a private placement exempt from registration under the Securities Act, characteristic of a dilutive equity issuance.","company_name":"Can-Fite BioPharma Ltd.","ticker":"CANF","filing_date":"2026-09-02","form":"6-K","submitted_at":null,"items":[{"id":34016,"accession_number":"0001213900-26-096480","item_number":"EX-99.1","item_title":"ea030438301ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Can-Fite announced entry into a definitive agreement for immediate exercise of warrants to purchase 1,591,738 ADSs at a reduced exercise price of $2.50 per ADS, generating approximately $4.0 million in gross proceeds. In consideration, the company will issue new unregistered warrants to purchase 3,183,476 ADSs—a 2:1 warrant issuance that is dilutive to existing shareholders. The new warrants are offered in a private placement exempt from registration under the Securities Act, characteristic of a dilutive equity issuance.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-02T13:06:37.487674+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34016,"accession_number":"0001213900-26-096480","item_number":"EX-99.1","item_title":"ea030438301ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Can-Fite announced entry into a definitive agreement for immediate exercise of warrants to purchase 1,591,738 ADSs at a reduced exercise price of $2.50 per ADS, generating approximately $4.0 million in gross proceeds. In consideration, the company will issue new unregistered warrants to purchase 3,183,476 ADSs—a 2:1 warrant issuance that is dilutive to existing shareholders. The new warrants are offered in a private placement exempt from registration under the Securities Act, characteristic of a dilutive equity issuance.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-02T13:06:37.487674+00:00","company_name":"Can-Fite BioPharma Ltd.","ticker":"CANF","filing_date":"2026-09-02"}]}